Neutralizing antibody response and SARS severity.
Identifieur interne : 002424 ( PubMed/Corpus ); précédent : 002423; suivant : 002425Neutralizing antibody response and SARS severity.
Auteurs : Mei-Shang Ho ; Wei-Ju Chen ; Hour-Young Chen ; Szu-Fong Lin ; Min-Chin Wang ; Jiali Di ; Yen-Ta Lu ; Ching-Lung Liu ; Shan-Chwen Chang ; Chung-Liang Chao ; Chwan-Chuen King ; Jeng-Min Chiou ; Ih-Jen Su ; Jyh-Yuan YangSource :
- Emerging infectious diseases [ 1080-6040 ] ; 2005.
English descriptors
- KwdEn :
- Adult, Antibodies, Viral (blood), Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Neutralization Tests, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (mortality), Severe Acute Respiratory Syndrome (physiopathology), Severe Acute Respiratory Syndrome (virology), Severity of Illness Index.
- MESH :
- chemical , blood : Antibodies, Viral.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- mortality : Severe Acute Respiratory Syndrome.
- physiopathology : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Adult, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Neutralization Tests, Severity of Illness Index.
Abstract
Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks. Patients with a longer illness showed a lower neutralizing antibody response than patients with a shorter illness duration (p = 0.008). When early responders were compared with most patients, who seroconverted on and after week 3 of illness, the small proportion (17.4%) of early responders (antibody detectable within 2 weeks) had a higher death rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a shorter survival time of <2 weeks (Fisher exact test, p = 0.013), and were more likely to be > 60 years of age (Fisher exact test, p = 0.01). Our findings have implications for understanding the pathogenesis of SARS and for SARS vaccine research and development.
DOI: 10.3201/eid1111.040659
PubMed: 16318725
Links to Exploration step
pubmed:16318725Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neutralizing antibody response and SARS severity.</title><author><name sortKey="Ho, Mei Shang" sort="Ho, Mei Shang" uniqKey="Ho M" first="Mei-Shang" last="Ho">Mei-Shang Ho</name><affiliation><nlm:affiliation>Academia Sinica, Taipei, Taiwan.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Wei Ju" sort="Chen, Wei Ju" uniqKey="Chen W" first="Wei-Ju" last="Chen">Wei-Ju Chen</name></author><author><name sortKey="Chen, Hour Young" sort="Chen, Hour Young" uniqKey="Chen H" first="Hour-Young" last="Chen">Hour-Young Chen</name></author><author><name sortKey="Lin, Szu Fong" sort="Lin, Szu Fong" uniqKey="Lin S" first="Szu-Fong" last="Lin">Szu-Fong Lin</name></author><author><name sortKey="Wang, Min Chin" sort="Wang, Min Chin" uniqKey="Wang M" first="Min-Chin" last="Wang">Min-Chin Wang</name></author><author><name sortKey="Di, Jiali" sort="Di, Jiali" uniqKey="Di J" first="Jiali" last="Di">Jiali Di</name></author><author><name sortKey="Lu, Yen Ta" sort="Lu, Yen Ta" uniqKey="Lu Y" first="Yen-Ta" last="Lu">Yen-Ta Lu</name></author><author><name sortKey="Liu, Ching Lung" sort="Liu, Ching Lung" uniqKey="Liu C" first="Ching-Lung" last="Liu">Ching-Lung Liu</name></author><author><name sortKey="Chang, Shan Chwen" sort="Chang, Shan Chwen" uniqKey="Chang S" first="Shan-Chwen" last="Chang">Shan-Chwen Chang</name></author><author><name sortKey="Chao, Chung Liang" sort="Chao, Chung Liang" uniqKey="Chao C" first="Chung-Liang" last="Chao">Chung-Liang Chao</name></author><author><name sortKey="King, Chwan Chuen" sort="King, Chwan Chuen" uniqKey="King C" first="Chwan-Chuen" last="King">Chwan-Chuen King</name></author><author><name sortKey="Chiou, Jeng Min" sort="Chiou, Jeng Min" uniqKey="Chiou J" first="Jeng-Min" last="Chiou">Jeng-Min Chiou</name></author><author><name sortKey="Su, Ih Jen" sort="Su, Ih Jen" uniqKey="Su I" first="Ih-Jen" last="Su">Ih-Jen Su</name></author><author><name sortKey="Yang, Jyh Yuan" sort="Yang, Jyh Yuan" uniqKey="Yang J" first="Jyh-Yuan" last="Yang">Jyh-Yuan Yang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16318725</idno><idno type="pmid">16318725</idno><idno type="doi">10.3201/eid1111.040659</idno><idno type="wicri:Area/PubMed/Corpus">002424</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002424</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neutralizing antibody response and SARS severity.</title><author><name sortKey="Ho, Mei Shang" sort="Ho, Mei Shang" uniqKey="Ho M" first="Mei-Shang" last="Ho">Mei-Shang Ho</name><affiliation><nlm:affiliation>Academia Sinica, Taipei, Taiwan.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Wei Ju" sort="Chen, Wei Ju" uniqKey="Chen W" first="Wei-Ju" last="Chen">Wei-Ju Chen</name></author><author><name sortKey="Chen, Hour Young" sort="Chen, Hour Young" uniqKey="Chen H" first="Hour-Young" last="Chen">Hour-Young Chen</name></author><author><name sortKey="Lin, Szu Fong" sort="Lin, Szu Fong" uniqKey="Lin S" first="Szu-Fong" last="Lin">Szu-Fong Lin</name></author><author><name sortKey="Wang, Min Chin" sort="Wang, Min Chin" uniqKey="Wang M" first="Min-Chin" last="Wang">Min-Chin Wang</name></author><author><name sortKey="Di, Jiali" sort="Di, Jiali" uniqKey="Di J" first="Jiali" last="Di">Jiali Di</name></author><author><name sortKey="Lu, Yen Ta" sort="Lu, Yen Ta" uniqKey="Lu Y" first="Yen-Ta" last="Lu">Yen-Ta Lu</name></author><author><name sortKey="Liu, Ching Lung" sort="Liu, Ching Lung" uniqKey="Liu C" first="Ching-Lung" last="Liu">Ching-Lung Liu</name></author><author><name sortKey="Chang, Shan Chwen" sort="Chang, Shan Chwen" uniqKey="Chang S" first="Shan-Chwen" last="Chang">Shan-Chwen Chang</name></author><author><name sortKey="Chao, Chung Liang" sort="Chao, Chung Liang" uniqKey="Chao C" first="Chung-Liang" last="Chao">Chung-Liang Chao</name></author><author><name sortKey="King, Chwan Chuen" sort="King, Chwan Chuen" uniqKey="King C" first="Chwan-Chuen" last="King">Chwan-Chuen King</name></author><author><name sortKey="Chiou, Jeng Min" sort="Chiou, Jeng Min" uniqKey="Chiou J" first="Jeng-Min" last="Chiou">Jeng-Min Chiou</name></author><author><name sortKey="Su, Ih Jen" sort="Su, Ih Jen" uniqKey="Su I" first="Ih-Jen" last="Su">Ih-Jen Su</name></author><author><name sortKey="Yang, Jyh Yuan" sort="Yang, Jyh Yuan" uniqKey="Yang J" first="Jyh-Yuan" last="Yang">Jyh-Yuan Yang</name></author></analytic><series><title level="j">Emerging infectious diseases</title><idno type="ISSN">1080-6040</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Viral (blood)</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neutralization Tests</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (mortality)</term><term>Severe Acute Respiratory Syndrome (physiopathology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neutralization Tests</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks. Patients with a longer illness showed a lower neutralizing antibody response than patients with a shorter illness duration (p = 0.008). When early responders were compared with most patients, who seroconverted on and after week 3 of illness, the small proportion (17.4%) of early responders (antibody detectable within 2 weeks) had a higher death rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a shorter survival time of <2 weeks (Fisher exact test, p = 0.013), and were more likely to be > 60 years of age (Fisher exact test, p = 0.01). Our findings have implications for understanding the pathogenesis of SARS and for SARS vaccine research and development.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16318725</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1080-6040</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Emerging infectious diseases</Title><ISOAbbreviation>Emerging Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Neutralizing antibody response and SARS severity.</ArticleTitle><Pagination><MedlinePgn>1730-7</MedlinePgn></Pagination><Abstract><AbstractText>Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks. Patients with a longer illness showed a lower neutralizing antibody response than patients with a shorter illness duration (p = 0.008). When early responders were compared with most patients, who seroconverted on and after week 3 of illness, the small proportion (17.4%) of early responders (antibody detectable within 2 weeks) had a higher death rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a shorter survival time of <2 weeks (Fisher exact test, p = 0.013), and were more likely to be > 60 years of age (Fisher exact test, p = 0.01). Our findings have implications for understanding the pathogenesis of SARS and for SARS vaccine research and development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Mei-Shang</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei-Ju</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hour-Young</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Szu-Fong</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Min-Chin</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Di</LastName><ForeName>Jiali</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yen-Ta</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ching-Lung</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Shan-Chwen</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Chung-Liang</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Chwan-Chuen</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Chiou</LastName><ForeName>Jeng-Min</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Ih-Jen</ForeName><Initials>IJ</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jyh-Yuan</ForeName><Initials>JY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Infect Dis</MedlineTA><NlmUniqueID>9508155</NlmUniqueID><ISSNLinking>1080-6040</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16318725</ArticleId><ArticleId IdType="pmc">PMC3367364</ArticleId><ArticleId IdType="doi">10.3201/eid1111.040659</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Infect Dis. 2002 Apr 15;185(8):1011-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11930309</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2003 Jun;9(6):718-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12781013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2003 May 23;52(20):461-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12807078</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2003 Oct;41(10):4521-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14532176</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Nov;77(21):11303-11</Citation><ArticleIdList><ArticleId IdType="pubmed">14557616</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2003 Nov-Dec;13(6):387-98</Citation><ArticleIdList><ArticleId IdType="pubmed">14625886</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Microbiol. 2003 Dec 2;97(1-2):31-44</Citation><ArticleIdList><ArticleId IdType="pubmed">14637036</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2003 Nov;9(11):1491-2</Citation><ArticleIdList><ArticleId IdType="pubmed">14725258</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 2004 Apr;136(1):95-103</Citation><ArticleIdList><ArticleId IdType="pubmed">15030519</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):287-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15030699</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):304-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15030702</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Apr 22;350(17):1731-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15102999</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 2004 Jun;203(2):622-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15141376</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2004 Aug 15;326(1):140-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15262502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2004 Sep;126(3):845-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15364765</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Virus Res. 1986;31:335-55</Citation><ArticleIdList><ArticleId IdType="pubmed">2428214</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1986 Nov;67 ( Pt 11):2539-42</Citation><ArticleIdList><ArticleId IdType="pubmed">3783130</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1990 Mar 1;322(9):580-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2304505</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1994 Nov;12(14):1311-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7856296</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1997 Mar;175(3):545-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9041324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vet Med Sci. 1998 Jan;60(1):49-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9492360</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clin Proc. 2004 Nov;79(11):1372-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15544014</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2005 Feb;75(2):185-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15602737</ArticleId></ArticleIdList></Reference><Reference><Citation>AJR Am J Roentgenol. 2005 Jan;184(1):255-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15615985</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):507-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15655773</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15616839</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(5):2910-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15709010</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15657466</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 10;361(9369):1615-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12747883</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002424 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002424 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16318725
|texte= Neutralizing antibody response and SARS severity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16318725" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |